Natale Quartuccio

@arnascivico.it

Nuclear Medicine
ARNAS Ospedali Civico, Di Cristina e Benfratelli

Natale Quartuccio


                           Download Compact PDF  
https://researchid.co/supernat84

RESEARCH INTERESTS

Oncology, osteosarcoma, brain tumors, PET, pediatrics, hypoxia, systematic reviews, meta-analysis, nuclear medicine.
94

Scopus Publications

2124

Scholar Citations

28

Scholar h-index

51

Scholar i10-index

Scopus Publications

  • Predictive Value of [18F]FDG PET/CT for Neoadjuvant Chemoradiotherapy Response in Nasopharyngeal Carcinoma
    Natale Quartuccio, Federico Sireci, Sabina Pulizzi, Stefania Nicolosi, Dante D’Oppido, et al.
    Journal of Clinical Medicine, 2025
    Introduction: Nasopharyngeal carcinoma (NPC) is a distinct malignancy of the head and neck with high prevalence in endemic regions and a strong association with Epstein–Barr virus (EBV). In locally advanced stages, neoadjuvant chemotherapy (NAC) followed by chemoradiotherapy improves outcomes, but response rates vary. Identifying early predictors of NAC response is essential for guiding personalized treatment strategies. This study aims to assess whether baseline [18F]FDG PET/CT parameters can predict NAC response in NPC patients. Methods: In this retrospective study, 27 patients with histologically confirmed, locally advanced (stage III) NPC underwent baseline [18F]FDG PET/CT prior to NAC between 2015 and 2023. Quantitative PET parameters including SUVmax, SUVmean, metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were extracted from the primary tumor. NAC response was assessed using RECIST 1.1 criteria and classified as responders (CR + PR) or non-responders (SD + PD). Group comparisons were performed using Student’s t-test. ROC analysis was used to identify optimal cut-off values. A p-value < 0.05 was considered significant. Results: The cohort included 20 males and 7 females (mean age: 60.8 ± 15.2 years). The predominant histotype was undifferentiated non-keratinizing carcinoma (92.6%). A total of 19 patients (70.4%) responded to NAC. Responders had significantly lower baseline SUVmax (10.9 ± 4.8 vs. 15.8 ± 4.1, p = 0.021), MTV (16.2 ± 12.4 vs. 27.8 ± 19.5 cm3, p = 0.045), and TLG (128.6 ± 98.2 vs. 218.7 ± 152.4, p = 0.038). SUVmean was also lower in responders (6.1 ± 2.1 vs. 9.3 ± 2.8), although not statistically reported. ROC analysis identified SUVmax > 12.5 and MTV > 20.0 cm3 as thresholds associated with poor NAC response. Conclusions: Baseline metabolic parameters from [18F]FDG PET/CT, particularly SUVmax and MTV, may assist stratification of NAC response in nasopharyngeal carcinoma. These biomarkers may facilitate pre-treatment stratification and guide more personalized therapeutic approaches. However, the limited sample size may affect the generalizability of these findings, and larger prospective studies are needed to confirm the results.
  • The role of FAPI PET/CT in patients with lymphoma: a systematic review
    Natale Quartuccio, Stefania Nicolosi, Sabina Pulizzi, Dante D’Oppido, Salvatore Ialuna
    Frontiers in Nuclear Medicine, 2025
    IntroductionFluorodeoxyglucose (FDG) PET/CT is typically the reference imaging method for assessing and tracking lymphomas. However, fibroblast activation protein inhibitor (FAPI) PET is being explored as a potentially useful option, especially when Fluorodeoxyglucose (FDG) scans do not show clear results.MethodsFor this systematic review, two researchers searched PubMed/MEDLINE and Cochrane CENTRAL for studies on FAPI PET/CT in lymphoma patients.ResultsThe literature search initially retrieved 249 articles. After removing duplicates and screening titles and abstracts, and full text, there was a final selection of 15 articles (3 original studies and 12 case reports), encompassing a total of 270 patients. The three original studies were judged to have a low risk of bias according to the QUADAS-2 criteria. The systematic review reveals that FAPI PET/CT exhibits lower diagnostic sensitivity than [18F]FDG PET/CT in lymphomas characterized by low FAP expression. Nevertheless, FAPI PET/CT retains potential as a complementary imaging modality.Discussion[18F]FDG PET/CT remains the gold standard in lymphoma imaging, but FAPI PET/CT can potentially provide supplementary information regarding the molecular characteristics of lymphomas. FAPI PET/CT may have prognostic and therapeutic implications. In particular, it could help identify lymphoma subgroups with distinct stromal environments, potentially serving as a prognostic biomarker. Further large-scale prospective studies are warranted to validate its role in lymphoma management.
  • The Objective Response and Disease Control Rates in Patients with Liver Metastastic Breast Cancer Receiving Transarterial Radioembolization: A Meta-Analysis
    Natale Quartuccio, Vincenzo Militano, Marco Pappalardo, Luca Filippi, Oreste Bagni, et al.
    Current Oncology, 2024
    Aim: To meta-analyze the utility of transarterial radioembolization (TARE) in patients with liver metastatic breast cancer (BC), based on the objective response rate (ORR) and disease control rate (DCR). Methods: A literature search was performed retrieving studies with (1) at least 10 patients with liver metastatic BC treated with TARE and (2) adequate information to derive ORR and DCR. The ORR is the ratio between patients with liver lesions showing complete response (CR) or partial response (PR) over the total number of patients treated with TARE; the DCR is the ratio between patients with CR, PR, or stable disease (SD) over the total number of patients treated with TARE. Results: Eighteen studies (650 patients) were eligible; the ORR of TARE resulted 50.71% (95% C.I.: 40.04–61.36) and the DCR resulted 88.37% (95% C.I.: 81.89–93.57). Taking into account resin spheres (395 patients), the ORR was 60.35% (95% C.I.: 46.55–73.36) and the DCR was 92.73% (95% C.I.: 87.17–96.80%). Considering glass spheres (144 patients), the ORR was 32.38% (95% C.I.: 18.43–48.16) and the DCR was 82.69% (95% C.I.: 59.29–97.26). Conclusions: This meta-analysis favors the use of TARE in patients with liver metastatic BC either with resin or glass spheres.
  • Head-to-Head Comparison of [18F]FDG PET Imaging and MRI for the Detection of Recurrence or Residual Tumor in Patients with Nasopharyngeal Carcinoma: A Meta-Analysis
    Natale Quartuccio, Sabina Pulizzi, Domenico Michele Modica, Stefania Nicolosi, Dante D’Oppido, et al.
    Cancers, 2024
    Background: This meta-analysis compared the diagnostic performance of [18F] fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) or PET versus Magnetic resonance imaging (MRI) in detecting recurrence or residual tumors at the primary site in patients with nasopharyngeal carcinoma (NPC). Methods: A comprehensive literature search was conducted in the PubMed/MEDLINE and CENTRAL databases to find studies with at least 20 patients with NPC undergoing both [18F]FDG PET/CT (or [18F]FDG PET) and MRI for detecting recurrence or assessing residual disease at the primary site. The pooled sensitivity and specificity of PET/CT and MRI were calculated with 95% confidence intervals (CIs) and compared. Results: Five studies, including 1908 patients (six patient groups), were included. PET imaging had higher sensitivity [93.3% (95% CI: 91.3–94.9%); I2 = 52.6%] compared to MRI [80.1% (95% CI: 77.2–82.8%); I2 = 68.3%], but the specificity of the two modalities was similar: 93.8% (95% CI: 92.2–95.2%; I2 = 0%) for PET/CT and 91.8% (95% CI: 90.1–93.4%; I2 = 94.3%) for MRI. The areas under the curve (AUCs) for PET/CT and MRI were 0.978 and 0.924, respectively, without significant difference (p = 0.23). Conclusions: This meta-analysis suggests that [18F]FDG PET imaging and MRI do not significantly differ in diagnostic performance. Nevertheless, [18F]FDG PET imaging shows higher sensitivity than MRI.
  • The Role of [18F]FDG PET/CT in Predicting Toxicity in Patients with NHL Treated with CAR-T: A Systematic Review
    Natale Quartuccio, Salvatore Ialuna, Sabina Pulizzi, Dante D’Oppido, Stefania Nicolosi, et al.
    Tomography, 2024
    CAR-T-cell therapy, also referred to as chimeric antigen receptor T-cell therapy, is a novel method in the field of immunotherapy for the treatment of non-Hodgkin’s lymphoma (NHL). In patients receiving CAR-T-cell therapy, fluorodeoxyglucose Positron Emission Tomography/Computer Tomography ([18F]FDG PET/CT) plays a critical role in tracking treatment response and evaluating the immunotherapy’s overall efficacy. The aim of this study is to provide a systematic review of the literature on the studies aiming to assess and predict toxicity by means of [18F]FDG PET/CT in patients with NHL receiving CAR-T-cell therapy. PubMed/MEDLINE and Cochrane Central Register of Controlled Trials (CENTRAL) databases were interrogated by two investigators to seek studies involving the use of [18F]FDG PET/CT in patients with lymphoma undergoing CAR-T-cell therapy. The comprehensive computer literature search allowed 11 studies to be included. The risk of bias for the studies included in the systematic review was scored as low by using version 2 of the “Quality Assessment of Diagnostic Accuracy Studies” tool (QUADAS-2). The current literature emphasizes the role of [18F]FDG PET/CT in assessing and predicting toxicity in patients with NHL receiving CAR-T-cell therapy, highlighting the evolving nature of research in CAR-T-cell therapy. Additional studies are warranted to increase the collected evidence in the literature.
  • An Uncommon Case of Pediatric Nasopharyngeal Carcinoma with Bone Metastases and Enchondromas Evaluated Using18F-FDG PET/CT
    Natale Quartuccio, Salvatore Ialuna, Salvatore Poma, Vincenzo Luca Lentini, Alessandro Pitruzzella, et al.
    Molecular Imaging and Radionuclide Therapy, 2024
    Nowadays, the utility of positron emission tomography/computed tomography (PET/CT) is well established in nasopharyngeal carcinoma (NPC). The incidence of NPC in the West population, especially in children, is very low. We present the first Italian case of a pediatric patient with NPC followed up with 18F-fluorodeoxyglucose (18F-FDG) PET/CT scan in addition to the standard follow-up imaging methods, including CT and magnetic resonance imaging. The 18F-FDG PET/CT scan was helpful in discriminating between metastatic and benign osseous lesions, thereby helping clinicians to determine the most appropriate therapeutic regimen. These findings support the clinical utility of 18F-FDG PET/CT in the diagnostic work-up of pediatric patients with NPC.
  • The Correlation of Body Mass Index with Risk of Recurrence in Post-Menopausal Women with Breast Cancer Undergoing Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
    Natale Quartuccio, Salvatore Ialuna, Sabina Pulizzi, Dante D’Oppido, Mauro Antoni, et al.
    Journal of Clinical Medicine, 2024
    Background: The aim of this study was to investigate whether high body mass index (BMI) increases the risk of recurrence and correlates with higher glucose uptake in recurrent lesions in post-menopausal female patients with breast cancer. Methods: A hospital database was searched to retrieve breast cancer patients who had undergone an [18F]FDG PET/CT scan before neoadjuvant chemotherapy and curative-intent surgery. BMI was calculated at the baseline [18F]FDG PET/CT scan. There was a median follow-up of 5 years after the baseline PET/CT scan to identify recurrence in the breast (T_rec); lymph nodes (N_rec); and distant locations (M_rec). Furthermore, SUVmax was measured at the sites of recurrence. A chi-square test was used to investigate any difference in the frequency of any recurrence, T_rec, N_rec, and M_rec, between overweight women (BMI ≥ 25 kg/m2) and women with a BMI < 25 kg/m2 (p < 0.05). SUVmax was compared using a t-test (p < 0.05) between the two groups. Results: A total of 142 post-menopausal patients (BMI: 26.84 ± 5.59; 84 overweight and 58 with normal weight) were retrieved from the database. There were 48 recurrences at the follow-up. The chi-square test demonstrated in overweight women an increased frequency of any recurrence (35 vs. 13; p = 0.025) and T_rec (15 vs. 2; p = 0.018) and a higher T_rec SUVmax (4.74 ± 2.90 vs. 1.85 ± 0.63; p = 0.09) compared to women with a BMI < 25 kg/m2. Conclusions: BMI seems to correlate with an increased rate of recurrence, especially in the breast, and a higher glucose uptake in post-menopausal patients with recurrent breast cancer.
  • The Influence of Additional Treatments on the Survival of Patients Undergoing Transarterial Radioembolization (TARE)
    Natale Quartuccio, Salvatore Ialuna, Daniele Scalisi, Fabio D’Amato, Maria Rosa Barcellona, et al.
    Current Oncology, 2024
    The aim of this study was to present our preliminary experience with transarterial radioembolization (TARE) using Yttrium-90 (90Y), compare the cancer-specific survival (CSS) of patients with hepatocellular carcinoma (HCC) and colorectal cancer (CRC) liver metastases undergoing TARE, and investigate the influence of additional treatments on CSS. Our database was interrogated to retrieve patients who had undergone TARE using Yttrium-90 (90Y) glass or resin microspheres. Kaplan–Meier curves and the log-rank test were employed to conduct survival analysis for the different groups (p < 0.05). Thirty-nine patients were retrieved (sex: 27 M, 12 F; mean age: 63.59 ± 15.66 years): twenty-three with hepatocellular carcinoma (HCC) and sixteen with CRC liver metastasis. Globally, the patients with HCC demonstrated a significantly longer CSS than those with CRC liver metastasis (22.64 ± 2.7 vs. 7.21 ± 1.65 months; p = 0.014). Among the patients with CRC liver metastasis, those receiving TARE and additional concomitant treatments (n = 10) demonstrated a longer CSS than the CRC patients receiving only TARE (9.97 ± 2.21 vs. 2.59 ± 0.24 months; p = 0.06). In the HCC group, there was a trend of a longer CSS in patients (n = 8) receiving TARE and additional treatments (27.89 ± 3.1 vs. 17.69 ± 3.14 months; p = 0.15). Patients with HCC seem to achieve a longer survival after TARE compared to patients with CRC liver metastases. In patients with CRC liver metastases, the combination of TARE and additional concomitant treatments may improve survival.
  • Applications of PET and SPECT in Patients with Autism Spectrum Disorder
    Anna Lisa Martini, Natale Quartuccio, Irene Giovanna Schiera, Valentina Berti, Luca Burroni, et al.
    Current Medical Imaging, 2024
    Autism spectrum disorder (ASD) consists of neurological development disorders that manifest before three years of age and affect social interactions, markedly restricting range of interests and activities, often associated with some degree of intellectual disability. Single-photon emission computed tomography (SPECT) and positron emission tomography (PET) are non-invasive imaging tools to investigate the function of the brain in vivo. SPECT and PET studies exploring rCBF and brain glucose metabolism in patients with ASD have been performed, providing important insights into the brain regions involved in ASD. Abnormalities in serotonergic, dopaminergic, GABAergic, cholinergic, and glutamatergic systems have been suggested to contribute to the observed distorted brain circuitry associated with ASD. However, the specificity of such abnormalities needs to be fully clarified because schizophrenia and other psychiatric diseases have been shown to present with comparable changes in neurotransmitter systems. Neuroinflammation could also play a role in the development of autism. Therefore, ASD is a complicated process involving a number of factors. It is mandatory to perform more research studies to determine the molecular cornerstone of ASD and to improve our comprehension of the clinical correlates of ASD.
  • Innovations in Positron Emission Tomography and State of the Art in the Evaluation of Breast Cancer Treatment Response
    Luigi Castorina, Alessio Danilo Comis, Angela Prestifilippo, Natale Quartuccio, Stefano Panareo, et al.
    Journal of Clinical Medicine, 2024
    The advent of hybrid Positron Emission Tomography/Computed Tomography (PET/CT) and PET/Magnetic Resonance Imaging (MRI) scanners resulted in an increased clinical relevance of nuclear medicine in oncology. The use of [18F]-Fluorodeoxyglucose ([18F]FDG) has also made it possible to study tumors (including breast cancer) from not only a dimensional perspective but also from a metabolic point of view. In particular, the use of [18F]FDG PET allowed early confirmation of the efficacy or failure of therapy. The purpose of this review was to assess the literature concerning the response to various therapies for different subtypes of breast cancer through PET. We start by summarizing studies that investigate the validation of PET/CT for the assessment of the response to therapy in breast cancer; then, we present studies that compare PET imaging (including PET devices dedicated to the breast) with CT and MRI, focusing on the identification of the most useful parameters obtainable from PET/CT. We also focus on novel non-FDG radiotracers, as they allow for the acquisition of information on specific aspects of the new therapies.
  • 99mTc-labeled colloid SPECT/CT versus planar lymphoscintigraphy for sentinel lymph node detection in patients with breast cancer: a meta-analysis
    Natale Quartuccio, Pierpaolo Alongi, Priscilla Guglielmo, Rosaria Ricapito, Gaspare Arnone, et al.
    Clinical and Translational Imaging, 2023
  • Brain positron emission tomography in idiopathic normal-pressure hydrocephalus: New 18F-fluorodeoxyglucose pattern in a long-known syndrome
    Angelina Cistaro, Natale Quartuccio, Arnoldo Piccardo, Giuseppe Meo, Ilaria Gandoglia, et al.
    Nuclear Medicine Communications, 2023
  • Detection of sentinel lymph node in vulvar cancer using 99mTc-labeled colloid lymphoscintigraphy, blue dye, and indocyanine-green fluorescence: a meta-analysis of studies published in 2010–2020
    Mariano Catello Di Donna, Natale Quartuccio, Vincenzo Giallombardo, Letterio Sturiale, Annachiara Arnone, et al.
    Archives of Gynecology and Obstetrics, 2023
  • 18F-FDG PET-Derived Volume-Based Parameters to Predict Disease-Free Survival in Patients with Grade III Breast Cancer of Different Molecular Subtypes Candidates to Neoadjuvant Chemotherapy
    Natale Quartuccio, Pierpaolo Alongi, Luca Urso, Naima Ortolan, Francesca Borgia, et al.
    Cancers, 2023
  • A Systematic Review Comparing Lymphoscintigraphy and Magnetic Resonance Imaging Techniques in the Assessment of Peripheral Lymphedema
    Salvatore Corrao, Natale Quartuccio, Federica Agugliaro, Pierpaolo Alongi, Letterio Sturiale, et al.
    Current Medical Imaging, 2023
  • The Role of Theragnostics in Breast Cancer: A Systematic Review of the Last 12 Years
    Michele Balma, Virginia Liberini, Ambra Buschiazzo, Manuela Racca, Alessio Rizzo, et al.
    Current Medical Imaging, 2023
  • Editorial: Case reports in PET imaging
    Silvia Taralli, Natale Quartuccio, Gaurav Malviya
    Frontiers in Medicine, 2022
  • The Value of Semiquantitative Parameters Derived from 18F-FDG PET/CT for Predicting Response to Neoadjuvant Chemotherapy in a Cohort of Patients with Different Molecular Subtypes of Breast Cancer
    Luca Urso, Laura Evangelista, Pierpaolo Alongi, Natale Quartuccio, Corrado Cittanti, et al.
    Cancers, 2022
  • Brain 18F-Florbetapir PET/CT Findings in an Early-onset Alzheimer Disease Patient Carrying Presenilin-1 G378E Mutation
    Angelina Cistaro, Natale Quartuccio, Laura Cassalia, Daniela Vai, Ugo Paolo Guerra, et al.
    Alzheimer Disease and Associated Disorders, 2022
  • Multimodal Clinical Approach for Treatment of Bone Metastases in Solid Tumors
    Giuliano Lo Bianco, Ezio Lanza, Salvatore Provenzano, Manuela Federico, Alfonso Papa, et al.
    Anesthesiology and Pain Medicine, 2022
  • Worldwide Disparities in Recovery of Cardiac Testing 1 Year Into COVID-19
    Andrew J. Einstein, Cole Hirschfeld, Michelle C. Williams, Joao V. Vitola, Nathan Better, et al.
    Journal of the American College of Cardiology, 2022
  • Correction to: Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas (European Journal of Nuclear Medicine and Molecular Imaging, (2021), 48, 12, (3925-3939), 10.1007/s00259-021-05352-w)
    R. Laudicella, N. Quartuccio, G. Argiroffi, P. Alongi, L. Baratto, et al.
    European Journal of Nuclear Medicine and Molecular Imaging, 2022
  • Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review
    Michele Balma, Virginia Liberini, Manuela Racca, Riccardo Laudicella, Matteo Bauckneht, et al.
    Frontiers in Medicine, 2022
  • [18F] Fluorothymidine Positron Emission Tomography Imaging in Primary Brain Tumours: A Systematic Review
    Priscilla Guglielmo, Natale Quartuccio, Virginia Rossetti, Monica Celli, Pierpaolo Alongi, et al.
    Current Medical Imaging, 2022
  • The Utility of Conventional Amino Acid PET Radiotracers in the Evaluation of Glioma Recurrence Also in Comparison with MRI
    Giulia Santo, Riccardo Laudicella, Flavia Linguanti, Anna Giulia Nappi, Elisabetta Abenavoli, et al.
    Diagnostics, 2022

RECENT SCHOLAR PUBLICATIONS

  • Predictive Value of [ 18 F]FDG PET/CT for Neoadjuvant Chemoradiotherapy Response in Nasopharyngeal Carcinoma
    N Quartuccio, F Sireci, S Pulizzi, S Nicolosi, D D’Oppido, S Ialuna
    Journal of Clinical Medicine 14 (18), 6508 , 2025
    2025
    Citations: 2
  • The role of FAPI PET/CT in patients with lymphoma: a systematic review
    N Quartuccio, S Nicolosi, S Pulizzi, D D’Oppido, S Ialuna
    Frontiers in Nuclear Medicine 5, 1589903 , 2025
    2025
    Citations: 5
  • The Objective Response and Disease Control Rates in Patients with Liver Metastastic Breast Cancer Receiving Transarterial Radioembolization: A Meta-Analysis
    N Quartuccio, V Militano, M Pappalardo, L Filippi, O Bagni, AM Moreci, ...
    Current Oncology 31 (11), 6879-6890 , 2024
    2024
    Citations: 3
  • The Objective Response and Disease Control Rates in Patients with Breast Cancer: a Meta-analysis
    N Quartuccio, S Ialuna, V Militano, M Pappalardo, L Filippi, O Bagni, ...
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 51, S682-S683 , 2024
    2024
  • Head-to-head Comparison of [ 18 F]FDG PET/CT and MRI for the Detection of Recurrence or Residual Tumor in Patients with Nasopharyngeal Carcinoma: a Meta …
    N Quartuccio, S Ialuna, S Pulizzi, S Nicolosi, D D'Oppido, AM Moreci
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 51, S477-S478 , 2024
    2024
  • Head-to-Head Comparison of [ 18 F]FDG PET Imaging and MRI for the Detection of Recurrence or Residual Tumor in Patients with Nasopharyngeal Carcinoma: A …
    N Quartuccio, S Pulizzi, DM Modica, S Nicolosi, D D’Oppido, AM Moreci, ...
    Cancers 16 (17), 3011 , 2024
    2024
    Citations: 4
  • 18F-FDG PET/BT Taraması ile Değerlendirilen, Kemik Metastazları ve Enkondromları Olan Nadir Bir Pediatrik Nazofaringeal Karsinom Olgusu
    N Quartuccio, S Ialuna, S Poma, VL Lentini, A Pitruzzella, GM Galfano, ...
    Molecular Imaging and Radionuclide Therapy , 2024
    2024
  • An Uncommon Case of Pediatric Nasopharyngeal Carcinoma with Bone Metastases and Enchondromas Evaluated Using 18F-FDG PET/CT
    N Quartuccio, S Ialuna, S Poma, VL Lentini, A Pitruzzella, GM Galfano, ...
    Molecular Imaging and Radionuclide Therapy 33 (2), 121 , 2024
    2024
    Citations: 2
  • The Role of [ 18 F]FDG PET/CT in Predicting Toxicity in Patients with NHL Treated with CAR-T: A Systematic Review
    N Quartuccio, S Ialuna, S Pulizzi, D D’Oppido, S Nicolosi, AM Moreci
    Tomography 10 (6), 869-879 , 2024
    2024
    Citations: 6
  • The Influence of Additional Treatments on the Survival of Patients Undergoing Transarterial Radioembolization (TARE)
    N Quartuccio, S Ialuna, D Scalisi, F D’Amato, MR Barcellona, MG Bavetta, ...
    Current Oncology 31 (3), 1504-1514 , 2024
    2024
    Citations: 1
  • The correlation of body mass index with risk of recurrence in post-menopausal women with breast cancer undergoing fluorodeoxyglucose positron emission tomography/computed …
    N Quartuccio, S Ialuna, S Pulizzi, D D’Oppido, M Antoni, AM Moreci
    Journal of Clinical Medicine 13 (6), 1575 , 2024
    2024
    Citations: 4
  • The Influence of Additional Treatments, Injected Activity and Mean Dose to the Tumor on the Overall Survival of Patients Undergoing Transarterial Radioembolization (TARE)
    N Quartuccio, S Ialuna, D Scalisi, F D'Amato, MR Barcellona, MG Bavetta, ...
    Preprints , 2024
    2024
  • Applications of PET and SPECT in patients with autism spectrum disorder
    AL Martini, N Quartuccio, IG Schiera, V Berti, L Burroni, A Cistaro
    Current Medical Imaging 20 (1), e15734056232408 , 2024
    2024
    Citations: 10
  • Innovations in positron emission tomography and state of the art in the evaluation of breast cancer treatment response
    L Castorina, AD Comis, A Prestifilippo, N Quartuccio, S Panareo, L Filippi, ...
    Journal of Clinical Medicine 13 (1), 154 , 2023
    2023
    Citations: 10
  • Brain positron emission tomography in idiopathic normal-pressure hydrocephalus: new 18F-fluorodeoxyglucose pattern in a long-known syndrome
    A Cistaro, N Quartuccio, A Piccardo, G Meo, I Gandoglia, IG Schiera, ...
    Nuclear Medicine Communications 44 (12), 1163-1167 , 2023
    2023
    Citations: 2
  • 99m Tc-labeled colloid SPECT/CT versus planar lymphoscintigraphy for sentinel lymph node detection in patients with breast cancer: a meta-analysis
    N Quartuccio, P Alongi, P Guglielmo, R Ricapito, G Arnone, G Treglia
    Clinical and translational imaging 11 (6), 587-597 , 2023
    2023
    Citations: 4
  • Does Body Mass Index correlate with risk of recurrence in patients with breast cancer undergoing [18F] FDG PET/CT?
    N Quartuccio, S Ialuna, S Pulizzi, D D'Oppido, M Antoni, AM Moreci
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 50 (SUPPL 1 … , 2023
    2023
  • Overall survival of patients undergoing transarterial radioembolization (TARE) and the influence of additional treatments, injected activity and mean dose to the tumor
    S Ialuna, N Quartuccio, D Scalisi, F D'Amato, MR Barcellona, MG Bavetta, ...
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 50 (SUPPL 1 … , 2023
    2023
  • The role of theragnostics in breast cancer: a systematic review of the last 12 years
    M Balma, V Liberini, A Buschiazzo, M Racca, A Rizzo, DG Nicolotti, ...
    Current Medical Imaging Reviews 19 (8), 817-831 , 2023
    2023
    Citations: 21
  • Detection of sentinel lymph node in vulvar cancer using 99m Tc-labeled colloid lymphoscintigraphy, blue dye, and indocyanine-green fluorescence: a meta-analysis …
    MC Di Donna, N Quartuccio, V Giallombardo, L Sturiale, A Arnone, ...
    Archives of Gynecology and Obstetrics 307 (6), 1677-1686 , 2023
    2023
    Citations: 32

MOST CITED SCHOLAR PUBLICATIONS

  • State of the art of 18 F-FDG PET/CT application in inflammation and infection: a guide for image acquisition and interpretation
    M Casali, C Lauri, C Altini, F Bertagna, G Cassarino, A Cistaro, AP Erba, ...
    Clinical and Translational Imaging 9 (4), 299-339 , 2021
    2021
    Citations: 203
  • Prevention of dental caries: A review of effective treatments
    C Sicca, E Bobbio, N Quartuccio, G Nicolò, A Cistaro
    Journal of clinical and experimental dentistry 8 (5), e604 , 2016
    2016
    Citations: 141
  • Pediatric Bone Sarcoma: Diagnostic Performance of 18 F-FDG PET/CT Versus Conventional Imaging for Initial Staging and Follow-Up
    N Quartuccio, J Fox, D Kuk, LH Wexler, S Baldari, A Cistaro, H Schöder
    American Journal of Roentgenology 204 (1), 153-160 , 2015
    2015
    Citations: 120
  • Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with chronic inflammatory bowel disease: a systematic review and a meta-analysis
    G Treglia, N Quartuccio, R Sadeghi, A Farchione, C Caldarella, ...
    Journal of Crohn's and Colitis 7 (5), 345-354 , 2013
    2013
    Citations: 90
  • The role of Fluorine-18-Fluorodeoxyglucose positron emission tomography in staging and restaging of patients with osteosarcoma
    N Quartuccio, G Treglia, M Salsano, MV Mattoli, B Muoio, A Piccardo, ...
    Radiology and Oncology 47 (2), 97-183 , 2013
    2013
    Citations: 78
  • 124I-MIBG: a new promising positron-emitting radiopharmaceutical for the evaluation of neuroblastoma
    A Cistaro, N Quartuccio, F Caobelli, A Piccardo, R Paratore, P Coppolino, ...
    Nuclear Medicine Review 18 (2), 102-106 , 2015
    2015
    Citations: 74
  • Advanced imaging techniques for radiotherapy planning of gliomas
    A Castellano, M Bailo, F Cicone, L Carideo, N Quartuccio, P Mortini, ...
    Cancers 13 (5), 1063 , 2021
    2021
    Citations: 71
  • Radiomics and prostate MRI: current role and future applications
    G Cutaia, G La Tona, A Comelli, F Vernuccio, F Agnello, C Gagliardo, ...
    Journal of imaging 7 (2), 34 , 2021
    2021
    Citations: 61
  • Predictive value of 18 F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study
    F Caobelli, P Alongi, L Evangelista, M Picchio, G Saladini, M Rensi, ...
    European journal of nuclear medicine and molecular imaging 43 (3), 404-413 , 2016
    2016
    Citations: 60
  • Radiomics Analysis of Brain [ 18 F]FDG PET/CT to Predict Alzheimer’s Disease in Patients with Amyloid PET Positivity: A Preliminary Report on the Application of …
    P Alongi, R Laudicella, F Panasiti, A Stefano, A Comelli, P Giaccone, ...
    Diagnostics 12 (4), 933 , 2022
    2022
    Citations: 52
  • Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies-a multicenter experience.
    A Cistaro, P Coppolino, N Quartuccio, C Altini, M Cucinotta, P Alongi, ...
    Hellenic journal of nuclear medicine 18 (2), 97-102 , 2015
    2015
    Citations: 45
  • Prediction of 2 years-survival in patients with stage I and II non-small cell lung cancer utilizing 18F-FDG PET/CT SUV quantification
    A Cistaro, N Quartuccio, A Mojtahedi, P Fania, PL Filosso, A Campenni, ...
    Radiology and oncology 47 (3), 219 , 2013
    2013
    Citations: 43
  • Comparison of 99m Tc-Labeled Colloid SPECT/CT and Planar Lymphoscintigraphy in Sentinel Lymph Node Detection in Patients with Melanoma: A Meta-Analysis
    N Quartuccio, LM Garau, A Arnone, M Pappalardo, D Rubello, G Arnone, ...
    Journal of clinical medicine 9 (6), 1680 , 2020
    2020
    Citations: 42
  • The Additional Value of 18 F-FDG PET and MRI in Patients with Glioma: A Review of the Literature from 2015 to 2020
    N Quartuccio, R Laudicella, A Vento, S Pignata, MV Mattoli, R Filice, ...
    Diagnostics 10 (6), 357 , 2020
    2020
    Citations: 41
  • Imaging and treatment of brain tumors through molecular targeting: Recent clinical advances
    F Zaccagna, JT Grist, N Quartuccio, F Riemer, F Fraioli, C Caracò, ...
    European Journal of Radiology 142, 109842 , 2021
    2021
    Citations: 37
  • Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2
    A Fiorentino, R Laudicella, E Ciurlia, S Annunziata, V Lancellotta, ...
    Critical reviews in oncology/hematology 139, 117-124 , 2019
    2019
    Citations: 37
  • The role of PET/CT in the evaluation of patients affected by limbic encephalitis: A systematic review of the literature
    N Quartuccio, F Caobelli, L Evangelista, P Alongi, M Kirienko, V De Biasi, ...
    Journal of Neuroimmunology 284, 44-48 , 2015
    2015
    Citations: 36
  • The role of PET/CT in the management of patients affected by head and neck tumors: a review of the literature
    G Cammaroto, N Quartuccio, A Sindoni, F Di Mauro, F Caobelli, ...
    European Archives of Oto-Rhino-Laryngology 273 (8), 1961-1973 , 2016
    2016
    Citations: 35
  • Comparison of 18 F-FDG PET/CT methods of analysis for predicting response to neoadjuvant chemoradiation therapy in patients with locally advanced low rectal …
    C Altini, A Niccoli Asabella, R De Luca, M Fanelli, C Caliandro, ...
    Abdominal Imaging 40 (5), 1190-1202 , 2015
    2015
    Citations: 33
  • Uncommon 18F-FDG-PET/CT findings in patients affected by limbic encephalitis: hyper-hypometabolic pattern with double antibody positivity and migrating foci of hypermetabolism
    A Cistaro, F Caobelli, N Quartuccio, P Fania, M Pagani
    Clinical Imaging 39 (2), 329-333 , 2015
    2015
    Citations: 33